 SAN DIEGO, Feb. 24, 2021 GLOBE NEWSWIRE -- Kura Oncology, Inc. Nasdaq: KURA, a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that its investigational drug, tipifarnib, has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration FDA for the treatment of patients with recurrent or metastatic HRAS mutant head and neck squamous cell carcinoma HNSCC with variant allele frequency 20 after disease progression on platinum-based chemotherapy. Tipifarnib is currently being evaluated in an ongoing registration-directed clinical trial AIM-HN in this indication of high unmet need. 